# AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct06767527/  
OnCo record `nct06767527` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ivonescimab, Paclitaxel / nab-paclitaxel in triple-negative breast cancer, run by Akeso, now recruiting.

## Summary

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer is a phase 3 interventional study registered as NCT06767527 by Akeso, with 416 participants planned, started 2025-02-07 and due to reach its primary completion in 2026-12. Interventions recorded: AK112, Nab-paclitaxel, Placebo. Conditions listed: Triple-Negative Breast Cancer (TNBC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06767527
- Phase: 3
- Setting: A Randomized, Controlled, Multi-center Phase III Clinical Study of AK112 Plus Nab-paclitaxel Versus Placebo Plus Nab-paclitaxel as First-line Treatment for Locally Advanced Unresectable or Metastatic Triple-negative Breast Cancer
- Sponsor: Akeso
- Enrolled: 416

## Sources

- ClinicalTrials.gov NCT06767527: https://clinicaltrials.gov/study/NCT06767527

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct06767527.json